At 6.0% CAGR, the Middle East & Africa Gastrointestinal Drugs Market is Projected to be Worth US$ 2,889.26 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa gastrointestinal drugs market was valued at US$ 1,814.42 in 2023 and is expected to reach US$ 2,889.26 million by 2031, registering a CAGR of 6.0% from 2023 to 2031. Increasing research investment for novel drug development and artificial intelligence-based techniques and strategic initiatives by companies are among the critical factors attributed to the Middle East & Africa gastrointestinal drugs market expansion.

Gastrointestinal diseases are becoming prevalent worldwide. Many research institutes are offering funding to accelerate the discovery of new methods for the treatment of gastrointestinal disorders. For instance, Yale School of Medicine receives over US$ 8 million per year in research funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK). The primary research areas include understanding mechanisms responsible for pancreatic inflammation and pancreatitis genetics and immunobiology of inflammatory bowel disease, as well as complications and treatment of IBD, cirrhosis, viral hepatitis, and liver cancer. In addition, the UNC School of Medicine, which is engaged in the advancement of understanding the impacts of gastrointestinal and liver diseases and developing new treatments, accounted for a gastrointestinal research funding that exceeds US$ 20 million annually. The UNC Center for Functional Gastrointestinal and Motility Disorders has been a top global center for research on constipation, irritable bowel syndrome, and fecal incontinence. The research includes translational studies on the stool microbiome and genetic contributions to IBS, the development and validation of diagnostic criteria, clinical studies of the physiological and psychological mechanisms for symptoms, epidemiological studies, and systems-based research on healthcare delivery.

Gastrointestinal clinical research has evolved over the past decade. The use of Artificial intelligence (AI) is becoming increasingly common in many areas, particularly in the medical field. AI has the potential to revolutionize the design of gastrointestinal clinical research. The integration of AI algorithms enables researchers to extract essential insights from enormous patient data sets, resulting in more accurate and personalized treatments for gastrointestinal conditions. Further, machine learning algorithms help analyze patient data, genetic profiles, and treatment outcomes to find predictive markers for therapy response. By precisely identifying patient subgroups that are most likely to benefit from particular interventions, researchers can optimize treatment strategies and enhance patient outcomes.

AI-powered image analysis has the potential to transform the field of diagnostic imaging in gastrointestinal medicine. Researchers can examine medical images, such as CT scans or endoscopic images, to detect and classify abnormalities with high accuracy by using deep learning algorithms. This technology facilitates the early detection and characterization of gastrointestinal lesions, enabling timely interventions and improving patient prognosis. For example, studies have shown the efficacy of AI algorithms in diagnosing and characterizing colorectal polyps during colonoscopy, reducing the need for unnecessary surgeries. With a US$ 98,700 grant from the Newcastle Permanent Charitable Foundation on research, researchers are able to utilize AI to develop new therapies for IBD and ulcerative colitis. The microbiome and intestinal stem cells are two key components that are significant drivers of IBD but are not targeted by current therapies. identifying therapies from the gut microbiome is a complex undertaking with vast amounts of data, which is why applying AI in such research helps a lot, as it can recognize patterns in enormous amounts of data. AI also enhances the quality of not only the diagnostic process but also of individualized therapeutic strategies.

Thus, increasing research investment for novel drug development and artificial intelligence-based techniques is anticipated to introduce new and innovative treatment solutions for gastrointestinal conditions, which are likely to bring new trends to the gastrointestinal drugs market in the coming years.

On the contrary, high cost of biologics hampers the growth of Middle East & Africa gastrointestinal drugs market.

Based on drug class, the Middle East & Africa gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics segment held 27.3% share of the Middle East & Africa gastrointestinal drugs market in 2023, amassing US$ 496.19 million. It is projected to garner US$ 798.65 million by 2031 to expand at 6.1% CAGR during 2023–2031.

By application, the Middle East & Africa gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held 30.7% share of the Middle East & Africa gastrointestinal drugs market in 2023, amassing US$ 557.80 million. It is projected to garner US$ 912.14 million by 2031 to expand at 6.3% CAGR during 2023–2031.

By route of administration, the Middle East & Africa gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held 67.8% share of the Middle East & Africa gastrointestinal drugs market in 2023, amassing US$ 1,230.70 million. It is projected to garner US$ 2,028.57 million by 2031 to expand at 6.4% CAGR during 2023–2031.

By distribution channel, the Middle East & Africa gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 49.3% share of the Middle East & Africa gastrointestinal drugs market in 2023, amassing US$ 894.79 million. It is projected to garner US$ 1,474.35 million by 2031 to expand at 6.4% CAGR during 2023–2031.

Based on country, the Middle East & Africa gastrointestinal drugs market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The South Africa held 29.3% share of Middle East & Africa gastrointestinal drugs market in 2023, amassing US$ 531.87 million. It is projected to garner US$ 862.53 million by 2031 to expand at 6.2% CAGR during 2023–2031.

Key players operating in the Middle East & Africa gastrointestinal drugs market are Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, AbbVie Inc, Bayer AG, and Pfizer Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com